This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
3/16/2022
greetings and welcome to the synthetic biologics fourth quarter and full year 2021 earnings conference call at this time all participants are in a listen only mode a question and answer session will follow the formal presentation if anyone should require operator assistance during the conference please press star 0 on your telephone keypad as a reminder this conference is being recorded I would now like to turn this conference over to your host, Mr. Chris Calabrese with LifeSci Advisors. Thank you, sir. You may begin.
Thank you, operator, and good afternoon, everyone. Welcome to the Synthetic Biologics 2021 Year-End Investor Conference Call. Leading the call today will be Stephen Shalcross, Chief Executive and Chief Financial Officer of Synthetic Biologics, Dr. Vince Wacher, Head of Corporate and Product Development of Synthetic Biologics, Dr. Manel Cascaio, General Director of VCN and European Operations, and Dr. Frank Tufaro, currently Head of Operations at VCN, are also on the call and will be available to answer questions during the Q&A session. Synthetic Biologics issued a press release this afternoon, which provided operational highlights and included the financial results for the quarter and year-ending December 31, 2021. The press release can be found in the Investors section of the company website at www.syntheticbiologics.com. syntheticbiologics.com, together with the annual report on Form 10-K for the year ended December 31st, 2021, which was filed today with the Securities Exchange Commissioner, SEC. In addition to the phone line, this call is being streamed live via webcast, which will be archived on the company website for 90 days. During this call, certain forward-looking statements regarding synthetic biologics and VCN biosciences, current expectations and projections about future events will be made. Generally, the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, estimates, and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, including those set forth in synthetic biologics filings with the SEC, many of which are difficult to predict. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information on this call is provided only as of the date of this call, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained on this conference call on account of new information, future events, or otherwise, except as required by law. With that, I'd like to turn the call over to Steve. Steve?
Thanks, Chris. Good afternoon, everyone, and thank you for joining our 2021 year-end investor conference call. We are extremely pleased with the significant advances over the past year that propelled our business forward, offered new opportunities to enhance our existing pipeline, and positioned us at the forefront of oncolytic virus development for cancer indications with high unmet needs. I'd like to begin by highlighting the recently completed acquisition of BCN Biosciences, a privately held clinical stage biotech company focused on developing a new oncolytic adenovirus or OV platform. With the VCN acquisition, the newly combined company is developing a portfolio of systemically administered, selectively replicating adenovirus therapies designed to break down the tumor stroma, which is a protective barrier that limits the efficacy of many cancer therapeutic agents. Breaking down this stroma is intended to increase tumor access by OVs, chemotherapies, and immune oncology products, ideally improving their anti-tumor effects. Importantly, degrading the stroma can also expose tumor antigens, turning cold tumors hot and enabling a sustained anti-tumor response by the patient's immune system. I'd like to now provide an overview of our pipeline and walk you through key updates. Our lead oncology product, BCN01, is a next-generation OB designed for intravenous and intravitral delivery. BCN01 has been administered to 72 cancer patients in Phase I clinical studies to date with a focus on pancreatic ductal adenocarcinoma, also known as PDAC, and retinoblastoma. BCNL1 was granted orphan drug designation in 2011 by the European Medicines Agency for the treatment of PDAC, and was granted orphan drug designation by the FDA in February this year for the treatment of retinoblastoma. If approved, orphan drug designation provides critical marking exclusivity, and we plan to take full advantage of the development benefits to which we are eligible under the orphan drug designation. We are highly encouraged by the regulatory support and the promising clinical safety and efficacy data generated to date. Building on this, in the second half of 2022, we plan to initiate an international multi-center phase two clinical study of intravenous VCN-01 in combination with standard of care chemotherapy. Gemcitabine and napaclitaxel are the two chemos that we plan to use in this clinical trial as first-line therapy in newly diagnosed metastatic PDAC patients. The study will be led by Dr. Manuel Hidalgo, an internationally renowned physician, scientist, and academic, and Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York Presbyterian Hospital, as well as a member of the Board of Directors at Bristol-Myers Squibb. The proposed Phase II clinical trial comprises a randomized open-label study to be conducted at sites across the U.S. and Europe. The study is projected to enroll up to 92 adult patients with first-line metastatic PDAC for whom established clinical standard of care therapy is chemotherapy. The proposed study, which has not yet been agreed to by regulators, is expected to have two treatment arms. In arm one, patients will receive standard of care chemotherapy. In arm two, patients will receive UCN01 administered seven days prior to standard of care chemotherapy. It is proposed that two doses of UCN01 will be administered approximately three months apart. If this study design is agreed to by regulatory agencies, we believe it will be one of the first clinical trials to include repeated systemic dosing of an oncolytic virus. Primary endpoints for the proposed study may include overall survival and safety and tolerability. Additional endpoints may include progression-free survival, objective response rate, and measures of biodistribution, virus replication, and immune response. Since this is anticipated to be a two-arm open-label study, we plan to monitor the study's progress very closely and may conduct an interim analysis as supported by the emerging data. Now moving to our planned clinical study in advanced retinoblastoma. We believe BCN01 holds tremendous promise as a novel rescue therapy for patients who fail standard therapy or as an adjunct to chemotherapy to improve outcomes for these patients. We are working closely with key opinionators and regulatory agencies to finalize the protocol for a Phase 2-3 pivotal study of intravitreal BCN01 as either an adjunct to chemotherapy or a potential rescue therapy in pediatric patients with advanced retinoblastoma. In addition to the planned company-sponsored studies in PDAC and retinoblastoma, BCN01 will also be evaluated in a number of investigator-sponsored studies, including a study at the University of Pennsylvania combining BCN01 with mesothelin-directed CAR-T cell therapy in pancreatic and ovarian cancer patients. and separate studies at the University of Leeds and University of Navarra evaluating VCN01 in patients with brain tumors. We look forward to a number of potentially exciting upcoming milestones from the planned diverse VCN01 clinical programs over the next 12 to 24 months. Our next product candidate, VCN11, is a modified version of VCN01 that incorporates a proprietary albumin binding domain in the virus's outer shell. BCN11 was designed to improve systemic delivery by enabling the virus to coat itself with host serum albumin and prevent inactivation by antiviral neutralizing antibodies. IND enabling studies are being planned and are expected to commence following the completion of ongoing preclinical studies and CMC activities. In parallel, while we drive our OV programs forward, clinical development for CIN4 and CIN20 continue to progress. Washington University continues to screen and enroll patients in our Phase 1b2a clinical study of CIN4 ribaximase in alginated comedopathic cell transplant, or HCT, recipients for the prevention of acute graft-versus-host disease in bone marrow transplant patients. The Phase 1b2a study is designed to assess the feasibility of using CIN4 in this specific patient population and to provide key information requested by the FDA regarding the safety and tolerability of CIN4 in patients with impaired intestinal barrier function. Last year, we announced that enrollment in patient dosing had commenced in the first of three sequential antibiotic cohorts that will each be administered a different IV beta-lactam antibiotic to treat fever following conditional therapy. In total, eight participants in each cohort will receive CIN4 and four will receive placebo. To date, we have dosed 15, 10 that are considered available patients in this study. If enrollment proceeds as planned, we may be positioned to announce as many as three interim data readouts during the next 12 to 18 months, with the first one anticipated from this first antibiotic cohort towards the end of the first half of 2022, pandemic conditions permitting. We have also advanced our CIN20 intestinal alkaline phosphatase program. The phase one placebo-controlled multiple ascending dose study of CIN20 in healthy volunteers has completed dosing and follow-up, and patient samples are undergoing pharmacokinetic and pharmacodynamic analysis. We expect to report top-line data during the second quarter of 2022. Results from this study and the previously completed phase one single ascending dose clinical study of CIN20 will guide the clinical development of CIN20 across multiple potential clinical indications that may include radiation neuropathy, celiac disease, nonalcoholic fatty liver disease, and NASH. As part of our strategic transformation into an oncology-focused company, we are exploring value-creating options around CIN4 and CIN20. CINFOR and CIN20 both have significant potential opportunity in non-oncology-related indications. We are currently evaluating the best path forward for these assets and whether to advance these programs internally or by out-licensing or partnering them. As we look to the year ahead, the projected progress of our newly combined clinical development pipeline is expected to deliver numerous upcoming milestones that have the potential to drive significant value for shareholders. Key near-term clinical milestones over the next six months include the initiation of ECN01 dosing in an investigator-sponsored study of brain tumors at the University of Leeds, the initiation of ECN01 dosing in combination with mesothelin-directed CAR T-cells, in the investigator-sponsored study of pancreatic and ovarian cancer at the University of Pennsylvania, a data readout from the first cohort of the SIN4 study in L-genetic HET patients, and top-line data from the multiple ascending dose study of SIN20 in healthy volunteers. During the second half of 2022, we expect to initiate key clinical trials, including the Phase II study of VCN01 in PDAC patients, and possibly a Phase 2a study of SIN20. Additionally, we anticipate the initiation of a Phase 2b3a pivotal study of BCN01 in retinoblastoma either by the end of the year or very early in 2023. Now, I'd like to turn briefly to our financial results for the year ended December 31, 2021. General and administrative expenses increased to $6.5 million for the year ended December 31, 2021 from $5 million for the year ended December 31, 2020. This increase is primarily comprised of consulting and legal costs related to the VCN acquisition, higher insurance costs, audit fees, and public relations expenses. Research and development expenses increased to $7.8 million for the year ended December 31, 2021 from $5.1 million for the year ended December 31, 2020. This increase was primarily the result of increased clinical trial expenses as we continued dosing patients in the Phase 1B2A clinical trial of SIN4, the dosing of healthy volunteers in the SAD and MAD Phase 1 clinical studies for SIN20, and higher indirect program costs for the year ended December 31, 2021, including an increase in manufacturing costs for SIN20. Turning briefly to the balance sheet, we ended 2021 with over $67 million of cash on hand at December 31, 2021, which we believe will provide a significant runway to both support our existing programs as well as help accelerate the development of VCN clinical pipeline, including VCN01 and VCN11 through the end of 2023, during which time We expect to achieve a number of important milestones, as I mentioned earlier. As previously announced, the VCN transaction was structured to preserve our strong balance sheet and enable the planned advancement of our combined clinical development pipelines. As previously disclosed, we acquired 100% of the outstanding equity of VCN, which will now operate as a wholly-owned subsidiary of Synthetic Biologics. The upfront consideration for the acquisition was $4.7 million in cash, plus the assumption of $2.4 million of VCN liabilities. In addition, certain VCN shareholders received 19.99% of the total outstanding shares of Synthetic Biologics common stock as of December 14th, 2021. The balance of the VCN purchase price includes up to $70.25 million in future payments, contingent upon the achievement specific phase two and phase three clinical and regulatory approval milestones. There will be no additional royalties or commercial sales milestones to the sellers. Assuming we meet these milestones, we believe the value created for shareholders will far exceed the payments made to VCN. With an advanced clinical pipeline and a strong cash position, we are more excited than ever about the outlook for the newly combined company. We believe the VCNA acquisition will be truly transformational, and we look forward to providing further updates as we continue to advance our combined technologies and products. With that, we're happy to take some questions.
You're reading a preview of the SYN Q4 2021 earnings call.
Free account.
